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Detection and specificity of autoantibodies against extractable nuclear antigens (ENA) play a critical role in
the diagnosis and management of autoimmune disease. Historically, the detection of these antibodies has
employed double immunodiffusion (DID). Autoantibody specificity was correlated with diagnoses by this
technique. Enzyme immunoassays have been developed by multiple manufacturers to detect and identify the
specificity ENA autoantibodies. To address the relationship of ENA detection by DID and enzyme immuno-
assay, the performances of five immunoassays were compared. These included two DID and three enzyme-
linked immunoassays (ELISA) (both screening and individual antigen profile kits). The sample set included
83 ENA-positive, antinuclear-antibody (ANA)-positive specimens, 77 ENA-negative, ANA-positive specimens,
and 20 ENA- and ANA-negative specimens. Sensitivity and specificity were calculated by two methods: first, by
using the in-house DID result as the reference standard, and second, by using latent class analysis, which
evaluates each kit result independently. Overall, the results showed that the ELISA methods were more
sensitive for detection of ENA autoantibodies than DID techniques, but presence and/or specific type of ENA
autoantibody did not always correlate with the patient’s clinical presentation. Regardless of the testing strategy
an individual laboratory uses, clear communication with the clinical staff regarding the significance of a
positive result is imperative. The laboratory and the clinician must both be aware of the sensitivity and
specificity of each testing method in use in the clinical laboratory.
A diagnosis of autoimmune disease in patients is based upon
clinical history, physical examination, and laboratory detection
of antinuclear antibodies (ANAs). A particular class of ANAs
specific for extractable nuclear antigens (ENA) was initially
described in 1959 (3). Since that time, many different anti-
ENA antibodies have been described. The detection of these
autoantibodies and identification of their specificity have be-
come well-established tools for the laboratory diagnosis of
several autoimmune diseases. Studies of patients with ENA
antibodies have shown that detection of these autoantibodies
may have both diagnostic and prognostic significance, and the
detection of anti-ENA antibodies has assumed an important
role in the management of these patients (5, 16, 22). In most
cases, ENA testing is ordered after an initial ANA screen. The
indications for use are to establish a diagnosis in patients with
suggestive clinical symptoms, to exclude a diagnosis of auto-
immune disease in patients with few or uncertain clinical signs,
to subclassify patients with a known diagnosis, and to monitor
disease activity.
Testing for anti-ENA antibodies has historically relied on
gel-based immunoprecipitation techniques such as double im-
munodiffusion (DID) and counterimmunoelectrophoresis (2,
14). The associations of specific types of ENA autoantibodies
with rheumatological diseases were established by using these
gel-based immunoassay techniques (15). In the last decade,
enzyme-linked immunoassay (ELISA) systems have been de-
veloped to detect and determine the specificity of anti-ENA
antibodies. ELISA systems permit more rapid processing of
more specimens with a faster turnaround time than gel-based
assays. ELISA-based methods may also have increased sensi-
tivity for detection of ENA antibodies. However, the increased
sensitivity of these ELISAs may influence the clinical relevance
of their detection because diagnostic specificity may be re-
duced (10, 12, 17, 24). As yet, a set of reference standards with
known antibody specificities against defined antigen prepara-
tions is not available for evaluation of various methods or kits.
Serum reference panels are available from the Association of
Medical Laboratory Immunologists (4), but the specificities of
these sera were determined by consensus results from multiple
laboratories. The purpose of this study was to address the
relationship between DID and ELISA methods for the detec-
tion and identification of anti-ENA antibodies by evaluating
and comparing two DID kits and three ELISA kits. We eval-
uated both screening ELISAs and monospecific antigen
ELISAs to determine anti-ENA specificity.
MATERIALS AND METHODS
This study was approved by the Human Investigational Review Board of the
University of North Carolina, Chapel Hill.
Kits. The immunoassay kits chosen for this study were based upon their
representation in the listing of immunoassays utilized by participants in the
College of American Pathologists proficiency surveys, as well as the manufac-
turer’s willingness to participate in this study by providing immunoassay kits.
Three manufacturers of screening and individual antigen ELISA systems are as
follows: Immuno Concepts (kit 2) (Sacramento, Calif.), INOVA Diagnostics,
Inc. (kit 3) (San Diego, Calif.), and Diamedix (kit 4) (Miami, Fla.). Two DID kits
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from INOVA Diagnostics, Inc. (kit 5) (currently in use in the Clinical Immu-
nology Laboratory at UNC Hospitals), and Immuno Concepts (kit 1) were
evaluated. The test procedures were performed according to the directions
supplied in the manufacturers’ package inserts.
Study population and specimens. The sample set used for this study consisted
of 180 patient specimens received in the clinical immunology laboratory at UNC
Hospitals for ENA autoantibody antibody testing. This set represents 1 year of
ENA testing at this institution, which is a tertiary-care hospital associated with a
medical school. Serum specimens from these patients were frozen at 70°C after
testing for clinical purposes. Based on the standard assays used in our laboratory
(testing for ENA by DID, ANA by indirect immunofluorescence using a Hep-2
substrate, and double-stranded DNA [dsDNA] by indirect immunofluorescence
using a Crithidia luciliae substrate), the sample set included 83 ENA-, ANA-, and
dsDNA-positive specimens, 77 ANA-positive, ENA- and dsDNA-negative spec-
imens, and 20 specimens that were negative for ENA, dsDNA, and ANA. The 83
specimens that were ENA positive by our DID testing represented 81% of the
total number of ENA antibody-positive specimens analyzed by the clinical im-
munology laboratory. All 180 of the specimens were tested for autoantibodies
directed against Smith (Sm), ribonucleoprotein (RNP), anti-Sjögren’s syndrome
A/RO (SSA), and anti-Sjögren’s syndrome B/La (SSB) with DID kit 5, our
standard laboratory immunoassay for ENA antibodies. A small fraction of these
specimens were also tested for autoantibodies directed against Scl-70 and Jo-1
with DID kit 5 as part of the previous routine testing requested by the physician.
For this study, testing was conducted on frozen aliquots from the original spec-
imens. All screening ELISAs, individual antigen profile ELISAs, and DID using
kit 1 were carried out on the same day according to the manufacturers’ kit
instructions. The specimens were tested on the individual antigen ELISA re-
gardless of their results on the initial screening ELISA, since both assays were set
up at the same time. Specificity for each of the four main ENA antigens (Sm,
RNP, SSA, and SSB) was determined. Testing of specimens by DID for detection
of Scl-70 or Jo-1 autoantibodies was based on whether the specimen had previ-
ously been tested by DID for the antigens or detection of Scl-70 or Jo-1 auto-
antibody by ELISA.
The medical records of the patients whose specimens yielded inconsistent
results by different methods were reviewed by an independent rheumatologist, to
determine the clinical diagnosis at the time that the clinical specimen was col-
lected. The reviewer was asked, based upon the patient’s clinical presentation
and symptoms at the time that the specimen was collected, to consider whether
a positive ENA result would be expected and, if so, whether anti-ENA specificity
might be expected to be present.
Statistical analysis. Two of the ELISA kit manufacturers reported results that
were called “borderline” or “equivocal.” For purposes of statistical analysis,
specimens (n  12) that gave equivocal or borderline results were eliminated
from the data set prior to statistical analysis. Sensitivity and specificity were
calculated by two methods. First, sensitivity and specificity were calculated by
using the kit 5 (DID) result as the reference standard. In this analysis, the
sensitivity and specificity of kit 5 are assumed to be 100%. Secondly, latent-class
analysis was used to calculate sensitivity and specificity for each of the kits tested
(18, 23). Using a maximum likelihood procedure, this method provides estimates
for all five kits without designating a reference standard. Although this method
assumes that the tests are independent, the method is robust to violations of this
assumption (18).
RESULTS
Comparison of screening ELISAs for detection of ENA au-
toantibodies. Concordance, sensitivity, and specificity were cal-
culated for each of the three screening ELISAs by using the
in-house DID (kit 5) as the reference standard. The overall
concordances between the screening immunoassays and the kit
5 DID for combined detection of Sm, RNP, SSA, and/or SSB
were 95, 91, and 93%, respectively, for kits 2, 3, and 4 (Table
1). The sensitivities of the screening ELISA (kits 2, 3, and 4)
were 91, 85, and 89%, respectively, with specificities of 100, 98,
and 98%. The concordance between kit 1 (DID) and the ref-
erence test (kit 5) was 98%, with a sensitivity of 96% and
specificity of 100%.
Using latent class analysis, the sensitivities of the screening
assays were 99 to 100% for the three ELISA kits and 90 to 92%
for the two DID kits (Table 2). Conversely, the two DID kits
had specificities of 99 and 100%, while specificities for detect-
ing anti-ENA antibodies were 98, 92, and 96% for ELISA kits
2, 3, and 4, respectively (Table 2).
Profile ELISAs to detect antigen-specific ENA antibodies.
Concordance, sensitivity, and specificity in relation to the in-
house DID (kit 5) were calculated for the three antigen-spe-
cific ELISAs and DID kit 1 for the four major antigens, Sm,
RNP, SSA, and SSB, regardless of the group that the specimen
was in (i.e., ANA and ENA positive, ANA positive and ENA
negative, or ANA and ENA negative [Table 3]). Compared to
kit 5, concordance and specificity were 98% for detection of
the four major antigens using kit 1. The sensitivities of kit 1
were 73% for detection of Sm antibodies, 100% for RNP
antibodies, and 92 and 78% for SSA and SSB antibodies,
respectively. The three ELISA profile kits performed similarly
as a group. Kit 3, overall, had more discordant results than the
other two ELISAs (kits 2 and 4) for the four major antigens
(Table 3). The average sensitivity of detection of the Sm anti-
gen by the kits tested compared to kit 5 was the lowest for the
four antigens tested (75%  9%). Average concordance be-
tween the other kits and kit 5 for detection of Sm was also
lower, on average, than for the other three antigens. Average
concordance for detection of Sm antigen was 91%  12%,
compared to 94%  7% for RNP, 95%  2% for SSA, and
94%  3% for SSB. The specificity of detection for all four
antigens was similar regardless of the kit used. Limited testing
was conducted for Jo-1 and Scl-70 antigens; however, in all
cases where the in-house DID (kit 5) was positive for either
antigen, kit 1 DID and all three ELISA profile kits for either
Jo-1 or Scl-70 were positive.
Using latent-class analysis, the ELISA kits had greater sen-
sitivity for detection of antibodies against Sm, RNP, and SSA
than the DID kits (Table 4). The sensitivity of detecting SSB
antibodies with DID was very low (64% and 69% for kits 1 and







1 98 96 100
2 95 91 100
3 91 85 98
4 93 89 98
a Screening ELISA kits (kits 2, 3, and 4) and one DID kit (kit 1) were
evaluated in comparison to DID kit 5 for detecting the presence of ENA auto-
antibodies in 177 serum specimens.
TABLE 2. Latent class analysis of ELISA screening and DID for
detection of autoantibodies against ENAa
Kit % Sensitivity(95% CI)
% Specificity
(95% CI)
1 90 (84–96) 100
2 100 98 (95–100)
3 99 (97–100) 92 (86–98)
4 99 (97–100) 96 (93–100)
5 92 (87–98) 99 (97–100)
a Sensitivity and specificity were calculated based on analysis of 180 serum
specimens to 95% confidence levels. CI, confidence interval.
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5) compared to ELISA kits 2 and 3, both at 100%. However,
ELISA kit 4 also had low sensitivity for detection of SSB at
55%. The specificity of the DID kits was 98% for detection
of the four major antigens tested. The ELISA kits also showed
similar results, except for kit 3, which had low specificity for Sm
(73%) and RNP (86%).
Evaluation of specimens with inconsistent results. Fifteen
specimens had varying results with screening and/or antigen
specific immunoassays. Fourteen of the fifteen specimens with
inconsistent results were from patients who were classified as
ANA positive and ENA negative (DID kit 5). Chart review
revealed that 11 of the 15 samples (67%) had either a previous
diagnosis of autoimmune disease or symptoms consistent with
a diagnosis of autoimmune disease (Table 5). ELISA kits de-
tected ENA antibodies in 10 of those samples, while DID
detected antibodies in only two of those samples. In both of
those samples (no. 10 and 11), ENA reactivity by both DID
and ELISA matched the predicted specificity. In four of the
eight (50%) samples that were ELISA positive and DID neg-
ative (no. 2, 3, 9, and 12), ELISA specificity in one or more of
the kits matched predicted ENA specificity.
There were three specimens (no. 6, 8, and 14) that were
more difficult to interpret due to symptoms not necessarily
consistent with autoimmune disease. However, for two of the
samples (no. 6 and 8), all the ELISAs showed reactivity with
SSA, and the samples were negative by DID. Sample 14, also
negative by DID, showed Jo-1 reactivity by two of the ELISA
kits, which was not predicted.
DISCUSSION
In recent years, ELISA methods have been developed to
detect the presence and specificity of anti-ENA autoantibod-
ies. This study was performed to compare the performance of
several ELISA kits with conventional gel-based assays cur-
rently in use in a tertiary-care hospital.
The determination of the test characteristics of these assays
is limited because no “perfect” reference standard is available.
In using kit 5 (DID) as the reference standard, we assumed it
had perfect characteristics. If a test is more sensitive, such as
many of the ELISAs, some true-positive specimens may be
misclassified as false positives, resulting in underestimation of
test sensitivity. To address this issue we used latent-class anal-
ysis, which does not require the designation of a reference
standard. Although this procedure assumes independence be-
tween the assays, the estimates are relatively robust to violation
of this assumption (18). Results of this study indicate that the
initial antibody screening ELISA had good correlation with the
DID for detecting anti-ENA antibodies. One can reasonably
assume that, based upon these results, the ELISA kits com-
mercially available will detect specimens that contain anti-
ENA antibodies. Both DID methods showed high levels of
agreement for detection of specific ENA autoantibodies. By
latent class analysis, the ELISA kits were more sensitive for
antibody detection than the DID kits (Table 2), which was not
unexpected, because other studies have drawn similar conclu-
sions (1, 9). Lock et al. found that some patients who do not
have systemic lupus erythematosus had levels of anti-Sm anti-
bodies that were detectable by ELISA (8). This type of non-
specificity may have important consequences, since the pres-
ence of anti-Sm is one of the diagnostic criteria described by
the American Rheumatism Association for a diagnosis of sys-
temic lupus erythematosus (15). The antigen source, native or
recombinant, and method of purification are critical to sensi-
tivity and specificity in relation to the Sm/RNP complex (7) and
to the SSA multichain antigen (13, 21). Conformational
changes, as a result of coating the plastic microwell, may result
in loss of conformational epitopes recognized by ENA anti-
bodies (6, 11). However, the DID technique may be more
specific for detecting clinically significant anti-ENA antibodies.







Sm 1 98 73 99
2 99 82 100
3 73 82 72
4 98 64 100
RNP 1 99 100 99
2 94 100 94
3 84 100 84
4 95 100 95
SSA 1 98 92 100
2 94 98 93
3 93 94 93
4 93 94 93
SSB 1 98 78 100
2 94 83 95
3 91 83 92
4 91 56 95
a One DID kit (kit 1) and three ELISA kits (kits 2, 3, and 4).
TABLE 4. Latent-class analysis of profile kitsa
Antigen Kit % Sensitivity(95% CI)
% Specificity
(95% CI)
Sm 1 89 (68–100) 99 (98–100)
2 100 100
3 100 73 (67–80)
4 78 (51–100) 100
5 100 99 (97–100)
RNP 1 90 (82–100) 99 (98–100)
2 100 97 (94–100)
3 100 86 (81–92)
4 100 98 (95–100)
5 88 (78–98) 100
SSA 1 86 (76–95) 100
2 98 (94–100) 97 (94–100)
3 98 (93–100) 97 (94–100)
4 98 (94–100) 97 (94–100)
5 90 (81–98) 100
SSB 1 64 (44–84) 100
2 100 99 (98–100)
3 100 97 (95–100)
4 55 (34–76) 96 (93–99)
5 69 (49–88) 98 (96–100)
a Sensitivity and specificity data were generated using latent-class analysis for
ENA profile testing of five immunoassay methods. CI, confidence interval.
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ELISA techniques are more likely to detect low affinity an-
tibodies than gel immunodiffusion methods (8, 19). The vari-
ation in results of the ELISA kits may reflect differences in
antigen preparations, possibly resulting in different antigen-
binding epitopes and/or the presence of contaminating anti-
gens; differences in antigen coating concentrations; different
buffers affecting binding of antibodies, and different cutoff val-
ues for determination of positive and negative. Other studies
have also shown inconsistent results between various ELISA
kits (17). Additional studies are needed to determine the rea-
sons for these inconsistencies, but this will be difficult to do
until a standardized set of control antigens is available.
A majority of the specimens with inconsistent results that
were noted in this study (67%) were from specimens with
lower ANA titers, which has been noted in other studies as well
(4). The lower ANA titers may reflect antibodies that have
lower binding avidities. Among specimens with inconsistent
results, review of the patient’s chart at the time of specimen
collection showed that most of the patients had either a diag-
nosis or symptoms of autoimmune disease. The major discrep-
ancy was due to the fact that the DID test was negative while
the ELISAs were positive. Overall, the agreement between the
kits for ENA specificity was good. Predicted ENA specificity
matched measured specificity in 50% of the specimens.
There is still no one ideal test that is both highly sensitive
and highly specific. So what is the strategy for anti-ENA test-
ing? The European Consensus Workshops recommends that
ENA testing be performed by two or more methods (20).
Given the trade-off between sensitivity and specificity between
the ELISA and DID methods, one might consider using the
ELISAs to screen sera for anti-ENA antibodies, followed by
DID testing of positive sera for identification of antibody spec-
ificity. Regardless of the testing strategy an individual labora-
tory selects, clear communication with the clinical staff regard-
ing the significance of a positive result is imperative. Clinicians
must be aware of the sensitivity and specificity of each testing
method used.
ACKNOWLEDGMENT
We thank L. D. Stein for consultation and chart review for patients’
specimens that gave inconsistent results.
REFERENCES
1. Bizzaro, N., R. Tozzoli, E. Tonutti, A. Piazza, F. Manoni, A. Ghirardello, D.
Bassetti, D. Villalta, M. Pradella, and P. Rizzotti. 1998. Variability between
methods to determine ANA, anti-dsDNA and anti-ENA autoantibodies: a col-
laborative study with the biomedical industry. J. Immunol. Methods 219:99–107.
2. Clark, G., M. Reichlin, and T. B. Tomasi, Jr. 1969. Characterization of a
soluble cytoplasmic antigen reactive with sera from patients with systemic
lupus erythematosus. J. Immunol. 102:107–122.
3. Holman, H. R., H. R. Deicher, and H. G. Kunkel. 1959. The LE cell and the
LE serum factors. Bull. N. Y. Acad. Med. 35:409–418.
4. James, K., A. B. Carpenter, L. Cook, R. Marchand, and R. M. Nakamura for
The Association of Medical Laboratory Immunologists Standards Commit-
tee. 2000. Development of the antinuclear and anticytoplasmic antibody
consensus panel by the Association of Medical Laboratory Immunologists.
Clin. Diagn. Lab. Immunol. 7:436–443.
5. Kavanaugh, A., R. Tomar, J. Reveille, D. H. Solomon, H. A. Homburger, et
al. 2000. Guidelines for clinical use of the antinuclear antibody test and tests
for specific autoantibodies to nuclear antigens. Arch. Pathol. Lab. Med.
124:71–81.
6. Lee, L. A., K. Alvarez, T. Gross, and H. B. Harley. 1996. The recognition of
human 60 kDa Ro ribonucleoprotein particles by antibodies associated with
cutaneous lupus and neonatal lupus. J. Investig. Dermatol. 107:225–230.
7. Lehmeier, T., K. Foulaki, and R. Luhrmann. 1990. Evidence for three dis-
tinct D proteins, which react differentially with anti-Sm antibodies, in the
cores of the major snRNPs U1, U2, U4/U6 and U5. Nucleic Acids Res.
18:6475–6479.
8. Lock, R. J., and D. J. Unsworth. 2001. Antibodies to extractable nuclear
antigens. Has technological drift affected clinical interpretation? J. Clin.
Pathol. 54:187–190.
9. Meiloff, J. F., I. Bantjes, J. De Jong, A. P. Van Dam, and R. J. T. Smeenk.
1990. The detection of anti-Ro/SS-A and anti-La/SS-B antibodies. A com-
parison of counterimmunoelectrophoresis with immunoblot, ELISA, and
RNA-precipitation assays. J. Immunol. Methods. 133:215–226.
10. Phan, T. G., R. C. W. Wong, and S. Adelstein. 2002. Autoantibodies to
extractable nuclear antigens: making detection and interpretation more
meaningful. Clin. Diagn. Lab. Immunol. 9:1–7.
11. Provst, T. T., L. S. Levin, R. M. Watson, M. Mayo, and H. Ratrie. 1991.
Detection of anti-Ro(SSA) antibodies by gel double diffusion and a “sand-
wich” ELISA in systemic and subacute cutaneous lupus erythematosus and
Sjogrens’s syndrome. J. Autoimmun. 4:87–93.
12. Slater, C. A., R. B. Davis, and R. H. Shmerling. 1996. Antinuclear antibody
testing. A study of clinical utility. Arch. Intern. Med. 156:1421–1425.
13. Slobbe, R. L., G. J. Pruijn, and W. J. Van Vernooij. 1991. Ro(SS-A) and
La(SS-B) ribonucleoprotein complexes: structure, functions and antigenicity.
Ann. Med. Interne (Paris). 142:1592–1599.
14. Tan, E. M., and H. G. Kunkel. 1966. Characteristics of a soluble nuclear
TABLE 5. Clinical data for specimens with inconsistent results of ENA autoantibody testinga
Sample ANA titer andpattern
Reactivity in: Diagnosis based on
chart review
Predicted ENA
reactivityKit 5 Kit 1 Kit 2 Kit 3 Kit 4
1 1:320, S; 1:320, H RNP Macular rash, positive ANA SSA/SSB
2 1:640, H Sm; RNP SLE; arthritis with rash Sm
3 1:640, H SSA Arthralgia, arthritis SSA/SSB (Sjogren’s syndrome), RNP
(MCTD)
4 1:160, S; 1:160, H RNP Polyarthralgia, fatigue (SLE past) SSA/SSB (Sjogren’s syndrome), SLE
(Sm)
5 1:640, H Arthralgia, positive ANA SSA
6 1:160, S; 1:160, H SSA SSA SSA Double vision None suspected; possibly SSA/SSB
7 1:160, S; 1:160, H Sm Arthralgia, arthritis None suspected; possibly SSA/SSB
8 1:80, H; 1:160, S SSA SSA SSA Diabetes None suspected
9 1:640, H Sm SLE Sm
10 1:40, S Sm Sm Sm, RNP Sm, RNP SSB SLE Sm
11 1:80, H SSA SSA SSA, SSB SSA Rash, Positive ANA SSA/SSB; subacute cutaneous LE
12 1:40, S; 1:40, H Sm, RNP Joint pain RNP
13 1:40, S RNP Sm, RNP RNP Arthralgia, myofibralgia None suspected; possibly SSA/SSB
14 1:40, S; 1:40, H Jo-1 (B) Sm, Jo-1 Bloating, decreased C4 and plts. SSA (SLE); Sm (SLE)
15 1:80, H RNP ITP Sm
a Results of antigen specific immunoassays and clinical information on discrepant specimens are given. Results were reviewed by a study-blinded rheumatologist for
prediction of anti-ENA specificity based upon patient chart review. Abbreviations: S, speckled; H, homogenous; (B), borderline; plts., platelets; ITP, idiopathic
thrombocytopenia purpura; MCTD, mixed connective tissue disease; LE, lupus erythematosus.
300 ORTON ET AL. CLIN. DIAGN. LAB. IMMUNOL.
antigen precipitating with sera of patients with systemic lupus erythematosus.
J. Immunol. 96:464–471.
15. Tan, E. M., A. S. Cohen, J. F. Fries, A. T. Masi, D. J. McShane, N. F.
Rothfield, J. G. Schaller, N. Talal, and R. J. Winchester. 1982. The 1982
revised criteria for the classification of systemic lupus erythematosus. Ar-
thritis Rheum. 25:1271–1277.
16. Tan, E. M. 1989. Antinuclear antibodies: diagnostic markers for autoimmune
diseases and probes for cell biology. Adv. Immunol. 44:93–151.
17. Tan, E. M., J. S. Smolen, J. S. McDougal, B. T. Butcher, D. Conn, R.
Dawkins, M. J. Fritzer, T. Gordon, J. A. Hardin, J. R. Kalden, R. G.
Lahita, R. N. Maini, N. F. Rothfield, R. Smeenk, Y. Takasaki, W. J. van
Venrooij, A. Wiik, M. Wilson, and J. A. Koziol. 1999. A critical evaluation
of enzyme immunoassays for detection of antinuclear autoantibodies of
defined specificities. I. Precision, sensitivity, and specificity. Arthritis
Rheum. 42:455–464.
18. Torrance-Rynard, V. L., and S. D. Walter. 1997. Effects of dependent errors
in the assessment of diagnostic test performance. Stat. Med. 16:2157–2175.
19. Van Duijnhoven, H. L. P., F. J. M. Van de Warenburg, R. J. W. P. Willems,
and A. A. M. Ermens. 1999. A comparison of ELISA assays as routine
diagnostic test for detection of autoantibodies against extractable nuclear
antigens. Clin. Biochem. 32:179–183.
20. Van Vernooij, W. J., P. Charles, and R. N. Maini. 1991. The consensus
workshops for the detection of autoantibodies to intracellular antigens in
rheumatic diseases. J. Immunol. Methods 140:181–189.
21. Van Vernooij, W. J., R. L. Slobbe, and G. J. M. Pruijn. 1993. Structure and
function of La and Ro RNPs. Mol. Biol. Rep. 18:113–117.
22. Von Muhlen, C. A., and E. M. Tan. 1995. Autoantibodies in the diagnosis of
systemic rheumatic diseases. Semin. Arthritis Rheum. 24:323–358.
23. Walter, S. D., and L. M. Irwig. 1988. Estimation of test error rates, disease
prevalence and relative risk from misclassified data: a review. J. Clin. Epi-
demiol. 41:923–937.
24. Wenzel, J., R. Bauer, T. Bieber, and I Bohm. 2000. Autoantibodies in pa-
tients with lupus erythematosus: spectrum and frequencies. Dermatology
201:282–283.
VOL. 11, 2004 EVALUATION OF ENA AUTOANTIBODY-BASED METHODS 301
